Sionna Therapeutics, Inc. Common Stock (SION) is a Healthcare · Biotechnology company listed on NASDAQ. Price $5.96 (-16.99%), Market cap $1.93B, 52-week low–high $12.72 ~ $45.95.
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in P
Financial statements, price targets, institutional (13F) holdings and related news for Sionna Therapeutics, Inc. Common Stock are updated in real time on BlackAll Trade.
Sionna Therapeutics, Inc. Common Stock trades at $5.96 (-16.99%). Real-time quotes and charts are available on BlackAll Trade.
Sionna Therapeutics, Inc. Common Stock has a market cap of about $1.93B.
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane